• Disease
  • Polycythaemia
  • Polycythaemia Vera
  • Giulia Benevolo

    Prominent publications by Giulia Benevolo

    KOL Index score: 8497

    PURPOSE: Continuous therapy (CT) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or death), but chemotherapy-resistant relapse may negatively impact overall survival (OS). Progression-free survival 2 (PFS2; time from random assignment until the second progression or death) may represent an additional tool to estimate outcome. This study evaluates the benefit of novel agent-based CT versus fixed duration of therapy (FDT) in patients with ...

    Also Ranks for: Continuous Therapy |  pfs1 pfs2 |  fixed duration |  diagnosed multiple |  pooled analysis
    KOL Index score: 8252

    BACKGROUND: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome.

    METHODS: A centralized electronic clinical database was created in 20 European hematology ...

    Also Ranks for: Patients Myelofibrosis |  discontinuation ruxolitinib |  blast phase |  loss response |  platelet count
    KOL Index score: 6986

    We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to ...

    Also Ranks for: Patients Cancer |  myeloproliferative neoplasms |  mpn diagnosis |  philadelphia negative |  case control
    KOL Index score: 6900

    BACKGROUND: There is no evidence that phlebotomy alone is sufficient to steadily maintain haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with phlebotomy alone.

    METHODS: In 2017, we launched the Low-PV study, a multicentre, open-label, two-arm, parallel-group, investigator-initiated, phase 2 randomised trial with a group-sequential adaptive ...

    Also Ranks for: Polycythaemia Vera |  50 patients |  janus kinase |  ropeginterferon alfa2b |  low dose
    KOL Index score: 6498

    Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-dose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a ...

    Also Ranks for: Elderly Patients |  multiple myeloma |  median pfs |  primary point |  triplet doublet
    KOL Index score: 5285

    In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating ...

    Also Ranks for: Spleen Response |  6 months |  patients myelofibrosis |  ruxolitinib rux |  platelet count
    KOL Index score: 5141

    Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, ...

    Also Ranks for: Arterial Thrombosis |  myeloproliferative neoplasms |  thrombotic events |  mpn patients |  case control
    KOL Index score: 5105

    Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment for newly diagnosed MM, particularly in patients with high-risk cytogenetics [del(17p), t(4;14) or t(14;16)]. We pooled together data from patients with newly diagnosed MM treated with VMP or ...

    Also Ranks for: Pooled Analysis |  multiple myeloma |  standardrisk patients |  bortezomib dexamethasone |  prednisone vmp
    KOL Index score: 4121

    BackgroundSeveral new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogenic factors (CAFs) of patients from a phase 3 trial of a MM treatment could have a prognostic and predictive value in terms of response to therapy and progression-free and overall survival and ...

    Also Ranks for: Multiple Myeloma |  bone marrow |  mm patients |  prognostic predictive |  angiogenic cytokines
    KOL Index score: 3212

    PurposeMaintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and ...

    Also Ranks for: Maintenance Patients |  induction consolidation |  multiple myeloma |  complete response |  retrospectively analyzed
    KOL Index score: 2899

    PurposeMyelofibrosis (MF) is a chronic myeloproliferative neoplasm characterised by an aggressive clinical course, with disabling symptoms and reduced survival. Patients experience a severely impaired quality of life and their families face the upheaval of daily routines and high disease-related financial costs. The aim of this study was to investigate the perceptions of Italian patients and their caregivers about living with MF and the burden of illness associated with MF.MethodsA ...

    Also Ranks for: Narrative Medicine |  patients caregivers |  cost illness |  italy male
    KOL Index score: 2564
    Also Ranks for: Polycythemia Vera |  essential thrombocythemia |  mysec project |  primary myelofibrosis |  80 biomarkers
    KOL Index score: 1508
    Also Ranks for: Myeloproliferative Neoplasms |  direct oral anticoagulants |  atrial fibrillation |  venous thromboembolism |  administration oral


    Giulia Benevolo: Influence Statistics

    Sample of concepts for which Giulia Benevolo is among the top experts in the world.
    Concept World rank
    ruxiol study #14
    median time icr #14
    rux iol #14
    ruxdfx therapy #14
    dfx iol #14
    rux‐iol study #14
    iron chelation response #14
    dfxrelated adverse events #14
    69 mf patients #14
    retrospective rux‐iol #14
    iol icr #14
    absence unexpected #17
    pfs2 maintenance #23
    maintenance pfs1 #23
    survival vgpr #23
    pfs2 partial #23
    955 ndmm patients #23
    response induction consolidation #23
    endpoints pfs1 #23
    free survival pfs1 #24
    induction consolidation maintenance #25
    maintenance myeloma patients #25
    dfx management #26
    33 478 #26
    vmp risk #27
    thrombocythemia myelofibrosis study #27
    benefited vmp #27
    75 years rdr #27
    vmp 257 patients #27
    rdr hazard ratio #27
    rdr vmp #27
    rdr standardrisk patients #27
    vera thrombocythemia myelofibrosis #27
    rdr highrisk patients #27
    mysec essential #27
    study mysec #27
    highrisk patients vmp #27
    vmp standard treatment #27
    fibrosis grade vera #27
    nct01093196 #31
    benefited risk #32
    vmp hazard #32
    lenalidomide transplant #32
    vmp treated #33
    post‐essential thrombocythemia #34
    rux dfx #34
    fdt pfs1 #38
    post‐polycythemia vera #38
    drug discontinuation discontinuation #40
    ruxolitinib chronic phase #40

    Key People For Polycythaemia Vera

    Top KOLs in the world
    Tefferi Tefferi
    essential thrombocythemia primary myelofibrosis polycythemia vera
    Tiziano Barbui
    polycythemia vera essential thrombocythemia myeloproliferative neoplasms
    Guido Finazzi
    polycythemia vera essential thrombocythemia myeloproliferative neoplasms
    polycythemia vera intrinsic factor pernicious anemia
    Heinz Gisslinger
    polycythemia vera multiple myeloma essential thrombocythemia
    Claire N Harrison
    speakers bureau board directors advisory committees

    Giulia Benevolo:Expert Impact

    Concepts for whichGiulia Benevolohas direct influence:Polycythaemia vera,  Multiple myeloma,  Pooled analysis,  Patients myelofibrosis,  Arterial thrombosis,  Myeloma patients,  Complete response,  Myeloproliferative neoplasms.

    Giulia Benevolo:KOL impact

    Concepts related to the work of other authors for whichfor which Giulia Benevolo has influence:Multiple myeloma,  Polycythemia vera,  Myeloproliferative neoplasms,  Essential thrombocythemia,  Elderly patients,  Maintenance therapy,  Primary myelofibrosis.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Division of Haematology, Città della Salute e della Scienza Hospital, Turin, Italy | SC Ematologia, AOU Città della Salute e della Scienza di Torino-Presidio Ospedaliero Molinette, Turin, Italy. | Hematology, AOU Città della Salute e della Scienza di